
Panelists discuss how hepcidin mimetics like rusfertide offer a novel approach to managing polycythemia vera (PV) by regulating iron metabolism, reducing iron overload, and improving hematocrit control, particularly in patients with iron deficiency or refractory disease, while also potentially enhancing disease management and quality of life when used alone or in combination with standard therapies like hydroxyurea or ruxolitinib.
















